Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.

Rothschild, Sacha I; Betticher, Daniel; Zenhäusern, Reinhard; Anchisi, Sandro; von Moos, Roger; Pless, Miklos; Moosmann, Peter; Popescu, Razvan A; Calderoni, Antonello; Dressler, Marco; Rauch, Daniel; Pederiva, Stefanie; Woelky, Regina; Papet, Claudia; Bühler, Vera; Borner, Markus (2019). Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. Cancer chemotherapy and pharmacology, 84(4), pp. 881-889. Springer 10.1007/s00280-019-03927-x

[img]
Preview
Text
280_2019_Article_3927.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (816kB) | Preview

PURPOSE The study aimed to investigate strategies to prevent and treat cetuximab-induced skin reactions and their perceived effectiveness in patients with metastatic colorectal cancer (mCRC) and recurrent/metastatic squamous cell cancer of the head and neck (SCCHN). METHODS This open-label, prospective observational study was conducted in Switzerland. RESULTS A total of 125 patients were included (n = 91 mCRC, n = 34 SCCHN; mean age 63.3 years; 73.6% males). The frequency of acneiform rash grade ≥ 2 increased from 12.6% at week 2 to 21.7% at week 16. The proportion of patients who reported no skin reaction decreased from 75.6% at week 2 to 43.3% at week 16. The most frequently used skin products at any time of observation were moisturizing (77.6%), lipid-regenerating (56.8%) or urea-containing products (52%), systemic antibiotics (49.6%), and vitamin K1 cream (43.2%). There was no clear effectiveness pattern for all product classes: in given patients, either the product showed no effect at all or a moderate/strong effect, consistently over time. CONCLUSIONS A great variety of low-cost general skin care products were commonly used. According to physician's preference, systemic antibiotics and vitamin K1 cream are an appropriate approach to prevent or treat cetuximab-related skin toxicity.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Rauch, Daniel and Borner, Markus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0344-5704

Publisher:

Springer

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

07 Jan 2020 09:26

Last Modified:

07 Jan 2020 09:28

Publisher DOI:

10.1007/s00280-019-03927-x

PubMed ID:

31444619

Uncontrolled Keywords:

Cetuximab Management Observational Practice survey Skin reactions

BORIS DOI:

10.7892/boris.137515

URI:

https://boris.unibe.ch/id/eprint/137515

Actions (login required)

Edit item Edit item
Provide Feedback